Whole Blood Biospecimen Collection for Subjects With Fanconi Anemia

Fanconi Anemia Clinical Trial

Official title:

Whole Blood Biospecimen Collection for Subjects With Fanconi Anemia

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05910853
• Other study ID #: SAN-09686
• Status: Terminated
• Start date: May 24, 2023
• Est. completion date: March 12, 2024

Study information

• Verified date: April 2024
• Source: Sanguine Biosciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The primary study objective is to collect biospecimen samples (e.g., blood) from participants diagnosed with Fanconi Anemia. The biospecimens will be used to create a biorepository that can be used to identify disease associated biomarkers and potential targets with immune and multi-omics profiling. The disease sample collection and analysis will be the foundation for an extensive network of biospecimen access and linked datasets for future translational research.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: March 12, 2024
• Est. primary completion date: March 12, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• The participant is willing and able to provide written informed consent

• The participant is willing and able to provide appropriate photo identification

• Participants aged 18 to 85

• Participants have been diagnosed with Fanconi Anemia complementation group A

Exclusion Criteria:

• Participants who are pregnant or are nursing

• Participants with a known history of HIV, hepatitis, or other infectious diseases Participants who have taken an investigational product in the last 30 days Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months

Related Conditions & MeSH terms

• Anemia
• Fanconi Anemia
• Fanconi Syndrome

Intervention

Diagnostic Test:
• Specimen Donation
Blood donation

Locations

Country	Name	City	State
United States	Sanguine Biosciences	Woburn	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Sanguine Biosciences

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Biospecimen Samples collect from patients with Fanconi Anemia participants diagnosed with Fanconi Anemia.	The primary study objective is to collect biospecimen samples (e.g., blood) from participants diagnosed with Fanconi Anemia. The biospecimens will be used to create a biorepository that can be used to identify disease associated biomarkers and potential targets with immune and multi-omics profiling. The disease sample collection and analysis will be the foundation for an extensive network of biospecimen access and linked datasets for future translational research.	1 year